Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

Tufia C. Haddad, Jun He, Ciara C. O’Sullivan, Beiyun Chen, Donald Northfelt, Amylou C. Dueck, Karla V. Ballman, Kathleen S. Tenner, Hannah Linden, Joseph A. Sparano, Judith O. Hopkins, Chamath De Silva, Edith A. Perez, Paul Haluska, Matthew P. Goetz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)'. Together they form a unique fingerprint.

Medicine & Life Sciences